ChondrosarcomaCIRCLENCT07360964
Clear Cell Chondrosarcoma in Italy
A study testing Molecular studies in people with Chondrosarcoma, run by Istituto Ortopedico Rizzoli at 1 site in Italy.
Trial summary
Clear cell chondrosarcoma of bone is considered a low-grade malignant tumor in the last WHO classification of soft tissue and bone tumors; however, it is reported that recurrences and metastasis can occur. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chondrosarcoma
- What is being tested?
- Molecular studies
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 77 participants
- Where
- 1 siteItaly
- Study dates
- 10 Sep 2025to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female patients with diagnosis of clear cell chondrosarcoma and chondrosarcoma with a clear cell component treated from 01 Jan 1982 to 31 Dec 2023
- Information available (date of primary tumor diagnosis, local treatments, systemic treatment, response to systemic treatment, date of progression) and date and status at last follow-up
- Imaging studies available for revision
- Histological slides available for revision
Who cannot join
- - Diagnosis different from clear cell chondrosarcoma or chondrosarcoma with a clear cell component;
- Absence of radiological and/or clinical data
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clear Cell Chondrosarcoma in Italy: Insights Into Radiological, Clinical and pathologicaL Features, With Emphasis on Prognosis (CIRCLE)
Clear cell chondrosarcoma of bone is considered a low-grade malignant tumor in the last WHO classification of soft tissue and bone tumors; however, it is reported that recurrences and metastasis can occur. Considering the uncertain prognosis of this rare tumor, with some cases that historically seems to pursue a bad prognosis, we decided to collect all the Italian cases of clear cell condrosarcoma, in order to better understand its natural history and prognosis.
- Conditions
- Chondrosarcoma
- Being tested
- Molecular studies
- Keywords
- clear cell chondrosarcoma, prognosis
- Medical subject headings
- Chondrosarcoma, Chondrosarcoma, Clear Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Molecular studiesGenetic
Molecolar studies to define possible prognostic parameters
| Study group | Role | What they receive |
|---|---|---|
| Patients | Experimental | Patients with a diagnosis of clear cell chondrosarcoma Receives: Genetic: Molecular studies |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prognostic accuracy
Ability of the model to predict overall survival, measured by AUC/C-index
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2026
- Study start10 Sep 2025
- Primary completion31 Dec 2025
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ChondrosarcomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istituto Ortopedico Rizzoli
- Sponsor type
- University, hospital or other
- Collaborators
- Azienda Ospedaliero, Universitaria Pisana, Gaetano Pini CTO, Milano, IRCCS Humanitas Research Hospital, Milano, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Ospedale "Morgagni - Pierantoni" di Forlì, A.O.U. Città della Salute e della Scienza, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07360964
- Sponsor's protocol ID
- CIRCLE
- Acronym
- CIRCLE
- Status last verified
- Jan 2026
- First submitted
- 8 Jan 2026
- Last updated
- 22 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clear Cell Chondrosarcoma in Italy: Insights Into Radiological, Clinical and pathologicaL Features, With Emphasis on Prognosis (CIRCLE)
- ClinicalTrials.gov ID
- NCT07360964
- Acronym / sponsor ID
- CIRCLE / CIRCLE
- Conditions
- Chondrosarcoma
- Keywords
- clear cell chondrosarcoma, prognosis
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 77 participants (actual)
- Lead sponsor
- Istituto Ortopedico RizzoliUniversity, hospital or other
- Collaborators
- Azienda Ospedaliero, Universitaria Pisana, Gaetano Pini CTO, Milano, IRCCS Humanitas Research Hospital, Milano, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Ospedale "Morgagni - Pierantoni" di Forlì, A.O.U. Città della Salute e della Scienza, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Study start
- 10 Sep 2025 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 22 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clear cell chondrosarcoma of bone is considered a low-grade malignant tumor in the last WHO classification of soft tissue and bone tumors; however, it is reported that recurrences and metastasis can occur. Considering the uncertain prognosis of this rare tumor, with some cases that historically seems to pursue a bad prognosis, we decided to collect all the Italian cases of clear cell condrosarcoma, in order to better understand its natural history and prognosis.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients | Experimental | Genetic: Molecular studiesPatients with a diagnosis of clear cell chondrosarcoma |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Male and female patients with diagnosis of clear cell chondrosarcoma and chondrosarcoma with a clear cell component treated from 01 Jan 1982 to 31 Dec 2023
- Information available (date of primary tumor diagnosis, local treatments, systemic treatment, response to systemic treatment, date of progression) and date and status at last follow-up
- Imaging studies available for revision
- Histological slides available for revision
Key exclusion criteria (2 listed)
- - Diagnosis different from clear cell chondrosarcoma or chondrosarcoma with a clear cell component;
- Absence of radiological and/or clinical data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Molecular studiesMolecolar studies to define possible prognostic parameters | Genetic | Patients |
Primary outcome
Prognostic accuracy
Time frame: At baseline
Ability of the model to predict overall survival, measured by AUC/C-index
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Chondrosarcoma
Active, not recruiting
High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull
Chordoma of Spine, Chordoma of Sacrum
RecruitingPhase 2
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma
RecruitingPhase 3
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Active, not recruitingPhase 2
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma
RecruitingObservational study
Clinical Applicability of Liquid Biopsy in Chondrosarcoma
Chondrosarcoma of the Bone
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Molecular studies in people with Chondrosarcoma, run by Istituto Ortopedico Rizzoli at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prognostic accuracy (time frame: At baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.